Business Segments

3 Months Ended

Mar. 29, 2025

Segment Reporting [Abstract]

Business Segments

13. Business Segments

The Company operates in one segment: ophthalmology. The Company develops, manufactures and markets medical devices. Our revenues arise from the sale of consoles, delivery devices, consumables, service, and support activities.

Revenue information shown by product group is as follows (in thousands):

	Three Months Ended
	March 29, 2025		March 30, 2024
Cyclo G6	$	3,181	$	2,953
Retina		6,645		6,774
Other(1)		2,070		2,034
Total revenues	$	11,896	$	11,761

(1) Includes service contract revenues of $334 thousand and $328 thousand recognized during the three months ended March 29, 2025 and March 30, 2024, respectively. Includes $364 thousand recognized revenue related to the exclusive distribution rights during both of the three months ended March 29, 2025 and March 30, 2024. Other also includes revenues from paid service, royalty, freight and legacy G probes.

Revenue information shown by geographic region, based on the sales destination, is as follows (in thousands):

	Three Months Ended
	March 29, 2025		March 30, 2024
United States	$	5,283	$	5,321
Europe, Middle East and Africa		2,861		3,698
Asia/Pacific Rim		3,360		2,444
Americas, excluding the U.S.		392		298
	$	11,896	$	11,761

Revenues are attributed to countries based on the location of end customers.

Other than the United States, the Netherlands accounted for at least 10% of the Company’s revenues during the three months ended March 29, 2025, representing 13.1%. Other than the United States, the Netherlands accounted for at least 10% of the Company’s revenues during the three months ended March 30, 2024, representing 21%. The United States accounted for 44.4% and 45.2% of revenues for the three months ended March 29, 2025 and March 30, 2024, respectively.